期刊文献+

国产卡维地洛对麻醉犬血流动力学的影响 被引量:1

HEMODYNAMIC EFFECTS OF DOMESTIC CARVEDILOL IN ANESTHETIC DOGS
下载PDF
导出
摘要 目的:观察国产卡维地洛(Car)对麻醉犬血流动力学的影响,了解该药对心血管系统的作用。方法:杂种家犬8只,戊巴比妥钠麻醉下记录心电、平均动脉压(MAP)、左心室内压(LVP)、心输出量(CO),观察静注Car0.1,0.3及1.0mg/kg后血流动力学各指标的变化。结果:静注Car后可引起麻醉犬MAP,心率(HR),LVP及其最大变化速率、左心室做功(LVW)及总外周血管阻力明显下降,给药后1min起效,药后1~5min达最大效能,且具有剂量依赖性,1mg/kg剂量组药效可持续至给药后45min;Car对麻醉犬CO及左心室舒张末压无明显影响。结论:Car具有较广泛的心血管效应,除通过扩张外周阻力血管降低血压外,尚具有降低HR和抑制心肌收缩性能的作用,表明国产Car兼具α肾上腺素受体和β肾上腺素受体拮抗剂特性,支持该药为具有S(-)和R(+)构型的外消旋化合物。 OBJECTIVE:Through observation on the hemodynamic action of domestic carvedilol to investigate its cardiovascular effects.METHODS:Domestic carvedilol was given to 8 anesthetic dogs by intravenous injection in a dose of 0.1,0.3 and 1.0 mg/kg and their mean arterial BP(MAP),left ventricular pressure(LVP),cardiac output(CO),and ECG were recorded and analyzed by computer.RESULTS:The MAP,HR,LVP,LVP±dp/dt max ,left ventricular work(LVW)and total peripheral resistance(TPR)of the anesthetic animals were significantly decreased by carvedilol injection with immediate onset of action and dosage dependent.For a dose of 1.0 mg/kg,these effects can be observed at 1 minute after drug given and maximum effects were observed at 1~5 minutes and lasted for 45 minutes.CONCLUSION:A broad cardiovascular effects were observed,beside a decrease in MAP induced by TPR reduction,decrease in HR and inhibition in contraction ability of heart can also be achieved.These results indicated that carvedilol is a recemic mixture with both β blockers’and α blockers’properties.
出处 《中国新药杂志》 CAS CSCD 1999年第5期318-320,共3页 Chinese Journal of New Drugs
关键词 卡维地洛 高血压 心肌缺血 血流动力学 药理 Carvedilol Hypertension Myocardial ischemia Hemodynamics Adrenergic antagonist Efficacy
  • 相关文献

同被引文献21

  • 1王小虹,vanZwietenPA.兼有α和β受体阻滞作用的药物药效学性质及其治疗潜力[J].国外医学(药学分册),1994,21(1):22-24. 被引量:8
  • 2Goto Y,Ogihara T.Effects of carvedilol on serum lipids in patient with essentialhypertension J Cardiovasc Pharmacol, 1991,18 ( suppL 4): S45.
  • 3Erika Von M, Gisbert S, Klaus S, et al. New Cardiovascular Drugs.New York: RavenPress, 1987,135-153.
  • 4Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity andmortality in patients with chronic heart failure. N Eng J Med, 1996,334(21): 1349-1355.
  • 5Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits Clinical Progressionin Patients with mild systems of heart failure. Circulation,1996,94(11) :2800-2806.
  • 6Australia/New Zealand Heart Failure Research CollaborativeGroup.Randomized,Placebo-controlled trial of carvedilol in patients with congestive heartfaiure due to ischaemic heart disease. Lancet, 1997,349: 375-380.
  • 7Krum H, Sackner-Bernstain JD, Goldsmith RL, et al. Doubleblind, Placebo-controlledstudy of the long-term efficacy of Carvedilol in patients with severe chronic heartfailure. Circulation,1995,92(6): 1499-1506.
  • 8Taylor SH, Omvik P. Hypertension and coronary artry disease: A therapeuticchallenge. J Cardiovasc Pharmacol, 1991,18(suppl4) :S39.
  • 9Das GP, Brood hurst P, Rattery EB, et al. Value of carvedilol in congestive heartfailure secondary to coronary artery disease. Am J Cardiol, 1990,66(1): 118.
  • 10Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacologicalproperties and therapeutic use in cardiovascular disorders [J] .Drugs, 1997,54:161-185.

引证文献1

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部